Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease.
Open Access
- 1 December 1975
- journal article
- case report
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 34 (6), 534-535
- https://doi.org/10.1136/ard.34.6.534
Abstract
A 69-year-old woman treated for 31 months with daily oral cyclophosphamide for refractory rheumatoid disease developed acute myelomonocytic leukemia 21/2 years after stopping the drug. The possibility of a casual association between the therapy and subsequent leukaemia is supported by the growing experience with cytotoxic agents.This publication has 5 references indexed in Scilit:
- Occurrence of cancer in immune deficienciesCancer, 1974
- Development of reticulum cell sarcoma during cyclophosphamide therapyArthritis & Rheumatism, 1974
- Immunosuppressive Drugs and Acute LeukemiaAnnals of Internal Medicine, 1973
- Guidelines for the Use of Cytotoxic Drugs in Rheumatic DiseasesArthritis & Rheumatism, 1971
- LEUKÆMOGENSThe Lancet, 1958